Neurocrine Biosciences NBIX
NASDAQ NBIX
$174.41 +5.27 (+3.12%)
At close: Nov 11, 2026 · 4:00 PM EST

Neurocrine Biosciences (NBIX) Short term Debt (2018 - 2024)

Updated

Analysis

Neurocrine Biosciences (NBIX) Short term Debt (2018 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Neurocrine Biosciences 17.13 Bn 13.21 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 122.80 Mn
Dec 31, 2023 170.10 Mn
Sep 30, 2023 169.90 Mn
Jun 30, 2023 169.70 Mn
Dec 31, 2022 169.40 Mn
Sep 30, 2022 169.20 Mn
Sep 30, 2020 425.00 Mn
Jun 30, 2020 419.50 Mn
Dec 31, 2019 408.80 Mn
Sep 30, 2018 383.65 Mn
API Access

Neurocrine Biosciences Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=NBIX&period=max&api_key=YOUR_API_KEY